Bayer AG said Thursday that it will partner with Evotec SE to develop therapies for polycystic ovary syndrome, a common hormone disorder that affects women.
Under the terms of the five-year collaboration agreement, German drug discovery company Evotec is eligible for 16.5 million euros ($18.4 million) in research payments as well as more than EUR330 million in milestone payments, plus royalties generated from sales of treatments that enter the market.
Bayer and Evotec will collaborate in the early development stage, while Bayer will be responsible for clinical trials and commercialization, it said.
The two companies have previously signed collaboration deals to develop drugs targeting endometriosis and kidney disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.